Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Diversified Royalty Acquired the Trademarks and Some Other Intellectual Property Used by Cheba Hut Franchising for $36M and Additional Consideration; Adds Ninth Royalty Stream and Second Based in U.S.

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Shares of ReNew Energy Global Plc RNW rose 4% after reporting fourth-quarter fiscal 2025 earnings of 10 cents/share, beating the Zacks Consensus Estimate of 7 cents. Shares of Northrop Grumman ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

The death of a second patient taking Sarepta Therapeutics' controversial gene therapy for Duchenne muscular dystrophy caused shares of Sarepta to plunge, and raised questions about the viability of ...

To date, over 900 Duchenne patients have been treated with delandistrogene moxeparvovec. "The signal for ALF is exceptionally rare and has only emerged in the non-ambulatory patients," Sarepta's CEO ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...